Barclays PLC Grows Position in Fennec Pharmaceuticals Inc (NASDAQ:FENC)

Barclays PLC lifted its position in shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) by 274.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 31,319 shares of the company’s stock after purchasing an additional 22,951 shares during the quarter. Barclays PLC owned about 0.11% of Fennec Pharmaceuticals worth $157,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp lifted its position in Fennec Pharmaceuticals by 2.2% during the third quarter. State Street Corp now owns 328,259 shares of the company’s stock valued at $1,641,000 after buying an additional 7,053 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Fennec Pharmaceuticals by 42.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock valued at $420,000 after acquiring an additional 20,602 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Fennec Pharmaceuticals during the 2nd quarter valued at $49,000. WINTON GROUP Ltd purchased a new stake in Fennec Pharmaceuticals during the 2nd quarter worth $409,000. Finally, Rhumbline Advisers boosted its position in Fennec Pharmaceuticals by 44.7% during the 2nd quarter. Rhumbline Advisers now owns 29,110 shares of the company’s stock worth $178,000 after purchasing an additional 8,987 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on FENC shares. Wedbush reissued an “outperform” rating and issued a $13.00 price objective on shares of Fennec Pharmaceuticals in a research report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Tuesday, December 17th. Finally, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Stock Up 0.3 %

Shares of Fennec Pharmaceuticals stock opened at $6.10 on Wednesday. Fennec Pharmaceuticals Inc has a 1-year low of $3.96 and a 1-year high of $11.49. The company has a market capitalization of $167.57 million, a PE ratio of -60.99 and a beta of 0.34. The company has a debt-to-equity ratio of 9.86, a current ratio of 7.80 and a quick ratio of 7.64. The business has a 50-day moving average of $5.51 and a 200-day moving average of $5.52.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Chris A. Rallis sold 6,409 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $6.14, for a total value of $39,351.26. Following the transaction, the director now directly owns 52,214 shares of the company’s stock, valued at $320,593.96. This represents a 10.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $6.08, for a total transaction of $60,800.00. Following the sale, the director now directly owns 83,863 shares of the company’s stock, valued at $509,887.04. The trade was a 10.65 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 19,636 shares of company stock valued at $115,437. Insiders own 10.98% of the company’s stock.

Fennec Pharmaceuticals Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.